Imunon, Inc. (NASDAQ:IMNN - Get Free Report) Director Donald P. Braun bought 25,000 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $1.18 per share, for a total transaction of $29,500.00. Following the transaction, the director now owns 25,597 shares of the company's stock, valued at $30,204.46. The trade was a 4,187.60 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Imunon Trading Down 2.5 %
Shares of NASDAQ:IMNN opened at $0.91 on Wednesday. Imunon, Inc. has a 12-month low of $0.48 and a 12-month high of $3.65. The business has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.02. The company has a market capitalization of $13.25 million, a PE ratio of -0.48 and a beta of 2.04.
Imunon (NASDAQ:IMNN - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. During the same quarter last year, the firm earned ($0.37) earnings per share. Equities research analysts predict that Imunon, Inc. will post -1.68 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently commented on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Imunon in a report on Friday, January 24th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Imunon in a report on Thursday, December 19th.
Get Our Latest Analysis on Imunon
Imunon Company Profile
(
Get Free Report)
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.